UAE Approves Pill for Obesity Treatment: Key Details Explained

In a major advancement for public health, the Emirates Drug Establishment has approved a new oral treatment for obesity, placing the UAE among the first countries globally to adopt the latest pharmaceutical innovations in chronic weight management.

The medication, Foundayo (orforglipron), developed by Eli Lilly and Company, is the first once-daily oral pill of its kind that can be taken without restrictions on food or water intake. It represents a significant shift in obesity treatment, particularly for patients seeking an alternative to injectable therapies.

A Growing Global Health Challenge

Obesity remains one of the most significant public health challenges worldwide, affecting more than one billion people. In the United Arab Emirates, it has been a key priority for health authorities due to its strong association with chronic diseases such as type 2 diabetes, cardiovascular disease, and certain cancers.

Medical experts increasingly emphasise that obesity is not merely a lifestyle issue, but a complex, chronic disease shaped by genetic, biological, and environmental factors. However, public understanding has yet to fully align with this view. A recent global study by Ipsos found that nearly two-thirds of individuals living with obesity still believe that diet and exercise alone are sufficient to manage the condition.

How the new treatment works?

Orforglipron belongs to a class of medicines known as GLP-1 receptor agonists, which work by regulating appetite and metabolism. By helping patients feel fuller for longer and reducing overall food intake, the treatment supports gradual and sustained weight loss when combined with lifestyle changes.

Clinical trials have demonstrated encouraging results. Patients taking the highest dose achieved an average weight reduction of up to 12.4 per cent, bringing oral treatments closer to the effectiveness typically associated with injectable options.

Importantly, the convenience of a once-daily pill is expected to improve patient adherence. Unlike some existing treatments that require injections or strict timing, orforglipron offers greater flexibility, making it easier to incorporate into daily routines.

UAE at the forefront

Health authorities say the approval reflects the UAE’s proactive approach to tackling obesity and expanding access to advanced treatments. By accelerating the availability of innovative medicines, the country aims to enhance patient outcomes and reduce the long-term burden of chronic disease.

Officials have also highlighted the importance of integrating such therapies into a broader care model. The new treatment is intended to complement — not replace — healthy lifestyle habits, including balanced nutrition and regular physical activity.

Changing perceptions

Encouragingly, awareness around obesity as a medical condition is growing in the UAE. Studies show that a high percentage of residents living with obesity are actively considering steps to manage their weight, and the use of prescription treatments is already above the global average.

The treatment is expected to become available to eligible patients in the UAE from May 2026, offering a new option for those seeking medically supported weight management.